A Drug-Drug Interaction Study of ALKS 5461 in Healthy Volunteers

NCT02272764 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2014-12-12

No results posted yet for this study

Summary

This study will evaluate the impact of Itraconazole on the pharmacokinetics of ALKS 5461.

Conditions

  • Pharmacokinetics

Interventions

DRUG

Itraconazole

Administered orally in a crossover design

DRUG

ALKS 5461

Administered sublingually in a crossover design

Sponsors & Collaborators

  • Alkermes, Inc.

    lead INDUSTRY

Principal Investigators

  • Sanjeev Pathak, MD · Alkermes, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02272764 on ClinicalTrials.gov